Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Humira's 'Unique' Number Of Patents Makes Biosimilar Entry Risky, Pfizer Says

Executive Summary

Pfizer wants to get its adalimumab biosimilar to market as soon as possible, but won’t say whether that’s before AbbVie's patents run out in 2023.
Advertisement

Related Content

Pfizer's Essential Health Leadership On Why US Biosimilars Will Take Off – Eventually
The New 180 Days? Humira Biosimilar Deals Give Amgen 150-Day Jump On Samsung
End In Sight: Humira Stacks Up 20 Years Of US Market Exclusivity
Biosimilar Legal Landscape: Lessons From 2017
Humira Biosimilar: Boehringer Faces Same Launch Hurdles As Amgen
AbbVie v. Amgen Round One: Humira Biosimilar Infringes 10 Patents, Suit Claims

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122875

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel